Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — FY2019 Earnings Presentation

47 slides from Aspen Pharmacare's earnings presentation, September 2019

  1. Slide 1: 2019 Annual Results Presentation

    2019 ANNUAL RESULTS PRESENTATION For the year ended 30 June 2019

  2. Slide 2: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S.

  3. Slide 3: Disclosure Note

    DISCLOSURE NOTE • Results separately disclose discontinued operations arising from the completed disposals of the Nutritionals business and non-core pharmaceutical portfolio in the Asia Pacific region • Adoption of new IFRS 9 (Financial instruments) and 15 (Revenue from contracts with customers)  I

  4. Slide 4: Financial Review

    FINANCIAL REVIEW

  5. Slide 5: Financial Summary

    FINANCIAL SUMMARY CONTINUING % Change vs PY R’million FY 2019 Reported CER Net revenue 38 872 1% -2% Gross profit 19 698 0% -2% Gross profit margin 50.7% 51.4% 50.7% Normalised EBITDA 10 824 -2% -4% Normalised EBITDA margin 27.8% 28.8% 28.1% Normalised tax (1 219) -3% -4% Normalised effective tax ra

  6. Slide 6: Segmental

    SEGMENTAL CONTINUING Regional Brands Sterile Focus Brands 2019 9785 17817 2019 8365 15267 2018 (CER) 9962 17736 2018 (CER) 8123 15618 • Regional Brands show revenue growth • Improved gross profit from Sterile Focus Brands, notwithstanding declines in the oncology portfolio despite lower sales Manufa

  7. Slide 7: Normalised EBITDA

    NORMALISED EBITDA CONTINUING R'million FY 2019 % of revenue FY 2018 (CER) % of revenue Gross profit 19 698 50.7% 20 195 50.7% Operating expenses (9 943) -25.6% (9 935) -24.9% Net other operating income 332 0.9% 265 0.7% Depreciation 737 1.8% 694 1.6% Normalised EBITDA 10 824 27.8% 11 219 28.1% Small

  8. Slide 8: Impairments

    IMPAIRMENTS CONTINUING R'million FY 2019 FY 2018 Comments relating to FY 2019 Intangible assets 2 412 623 Impairment of intangibles is 3.3% of opening book value Oncology portfolio 754 Increasing generic competition driving prices down Anaesthetics 264 Offset by equal release of deferred payable no

  9. Slide 9: Currency Impact

    CURRENCY IMPACT CONTINUING Contribution to Contribution to Average FX rates to ZAR Normalised FY 2019 FY 2018 H1 2019 revenue EBITDA EUR 29% 6% 16.19 15.33 16.34 AUD 11% 19% 10.15 9.97 10.27 CNY 7% 16% 2.08 1.97 2.07 USD 6% -17% 14.19 12.86 14.19 4% • ZAR contribution  Revenue: 19%  Normalised EBI

  10. Slide 10: Effective Tax Rates

    EFFECTIVE TAX RATES CONTINUING 29,3% 30% • The Group’s effective tax rate spiked during FY 2016 and FY 2019 due to 25% 20,5%  The write-off arising from the termination of the Venezuelan 22,2% 18,0% operations in FY 2016 20%  Higher impairments in FY 2019 20,6% 19,5% 16,6% 15% 17,1% 15,9% 15,4% •

  11. Slide 11: Reconciliation of CER NHEPS

    RECONCILIATION OF CER NHEPS CONTINUING Cents FY 2019 FY 2018 (CER) Basic earnings per share (EPS) 595.0 1 238.6 Profit on sale of property, plant and equipment 3.7 - Impairment of property, plant and equipment 92.5 11.2 Impairment of intangible assets 498.1 167.5 Reversal of impairment of PPE (3.9)

  12. Slide 12: Working Capital

    WORKING CAPITAL CONTINUING R’million FY 2019 FY 2018 (CER) • Strong cyclical unwind of working capital in H2 2019 of R875 million Net Working capital - comparable base* 16 906 16 508 • Benefited from lower than planned inventory levels due to: Net Working capital - excl. Oss 12 096 11 911  Supply c

  13. Slide 13: Capital Expenditure

    CAPITAL EXPENDITURE PPE CAPEX IN R’MILLION 2600 2442 2145 1500 H2 2019 1 800 1200 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 • Total capex on strategic projects has increased from R4.5 billion to Actual Planned R4.9 billion largely due to unfavourable forex adjustments • Expected first commercial produ

  14. Slide 14: Borrowings

    BORROWINGS ANALYSIS OF NET BORROWINGS Key Indicators FY 2019 H1 2019 FY 2018 Normalised net funding costs^ (1 893) ( 861) (1 819) Gearing 42% 51% 49% Net Debt/EBITDA * 3.6x 4.4x 3.8x Interest cover ratio 4.7x 5.4x 6.2x Effective interest rate for the period ** 3.81% 3.59% 4.00% Cash 8 977 9 868 11 1

  15. Slide 15: Net Borrowings Bridge

    NET BORROWINGS BRIDGE Transaction related 1 016 5 644 46 780 46 721 Operations related -59 -13 340 38 984 1 437 -75 -6 002 3 583 South Africa - ZAR 23% International - EUR Net Borrowings FX impact Net Borrowings 69% Payment of Acquisition of Proceeds on Cashflow from Capex Distribution to Other Net

  16. Slide 16: Key Cash Flow Commitment Trends

    KEY CASH FLOW COMMITMENT TRENDS R'million FY 2018 FY 2019 FY 2020 Future trend / Comments Capital expenditure - PPE 2 145 2 442 2 600 Declining sharply after FY 2020 and then stabalising - refer to slide 13 Capital expenditure - Intangible assets 6 083 1 522 700 Opportunity dependent, including in F

  17. Slide 17: Group Performance Review

    GROUP PERFORMANCE REVIEW

  18. Slide 18: Group Revenue

    GROUP REVENUE CONTINUING Developed markets Emerging markets R’million FY 2019 FY 2018 % change FY 2018 (CER)* % change -2% CER growth +1% CER growth Commercial Pharma** 33 084 32 190 3% 33 354 -1% R14,5bn; Regional Brands 17 817 17 321 3% 17 736 0% 44% R18,6bn; Sterile Focused Brands 15 267 14 869 3

  19. Slide 19: Commercial Pharma – By Geography

    COMMERCIAL PHARMA – BY GEOGRAPHY CONTINUING – Resilience in the broad geographic exposure Aspen regions Europe CIS R'million FY 2019 FY 2018 (CER)* % change (excluding Europe CIS) -7% CER +2% CER growth growth Asia Pacific 10 387 10 044 3% R9.9bn; 30% Europe CIS ** 9 897 10 639 -7% R23.2bn; Africa &

  20. Slide 20: Commercial Pharma - Europe CIS

    COMMERCIAL PHARMA - EUROPE CIS CONTINUING – Addressing underperformance Regional Brands in Europe CIS, % CER growth * R'million FY 2019 FY 2018 (CER) % change 1% Regional Brands 2 144 2 332 -8% Sterile Focused Brands 7 753 8 307 -7% Thrombosis 5 279 5 629 -6% -8% Anaesthetics 2 474 2 678 -8% Total 9

  21. Slide 21: Commercial Pharma – Aspen Regions, Excluding Europe CIS

    COMMERCIAL PHARMA – ASPEN REGIONS, EXCLUDING EUROPE CIS CONTINUING – Satisfactory performance R'million FY 2019 FY 2018 (CER)* % change Americas; Asia Pacific 10 387 10 044 3% Africa & 18% Middle Regional Brands 4 651 4 505 3% East; 6% Asia Pacific; Sterile Focused Brands 5 736 5 539 4% 76% Africa &

  22. Slide 22: Commercial Pharma – Group Regional Brands

    COMMERCIAL PHARMA – GROUP REGIONAL BRANDS CONTINUING – Strong brand equity • SSA and Australasia account for 63% of Group Regional Brands America's; • Australasia +5% , OTC performance +8% Europe CIS; 14% Asia Pacific; 26% 12% • SSA business restructured into Aspen and Ethicare for heightened custom

  23. Slide 23: Sterile Focus Brands - Anaesthetics

    COMMERCIAL PHARMA –STERILE FOCUS BRANDS - ANAESTHETICS CONTINUING OPERATIONS - Anaesthetics constrained by supply -2% 8840 8683 China; 23% +4% CER More Less constrained^ 4040 4202 constrained supply; 52% Japan; 15% More constrained** LatAm; 10% -7% CER 4800 4481 2018 (CER) 2019 Anaesthetics R8,7bn A

  24. Slide 24: Sterile Focus Brands – Thrombosis

    COMMERCIAL PHARMA – STERILE FOCUS BRANDS – THROMBOSIS CONTINUING OPERATIONS - Biosimilar impact in Europe Aspen LMWH * Originator enoxaparin^ 9.0% -1% 5.2% -9% -14% 1.7% -12% -19% 0.4% -21% Q3 CY 2018 Q4 CY 2018 Q1 CY 2019 Q2 CY 2019 Dec-16 Dec-17 Dec-18 Jun-19 Aspen LMWH portfolio in Europe CIS, 2

  25. Slide 25: Sterile Focus Brands – Thrombosis

    COMMERCIAL PHARMA – STERILE FOCUS BRANDS – Thrombosis CONTINUING OPERATIONS - Consistent overall performance +5,4% CAGR if China is annualised in +1,7% CAGR if China is annualised in FY 2017 FY 2017 2% 6431 6584 6778 6584 1% 246 215 6118 261 215 5664 1090 Other 282 888 Other 836 1090 283 Asia Pacifi

  26. Slide 26: Aspen Business Model

    ASPEN BUSINESS MODEL A GLOBAL MULTINATIONAL BUSINESS HAS BEEN ESTABLISHED > R10 BILLION NORMALISED EBITDA IN FY 2019 A DYNAMIC MODEL THE ASPEN GROWTH MODEL REQUIRES EFFICIENT PORTFOLIO RENEWAL • Organic growth • Adaptation to changing circumstances is • Value created in our products is • Efficient p

  27. Slide 27: Aspen Business Model Continued

    ASPEN BUSINESS MODEL CONTINUED ORGANIC PERFORMANCE FREE CASH FLOW GENERATION & DEBT SERVICING • Many regions delivering organic growth • Debt has been reduced by 27% in last six months • Europe CIS working to a solution • Operating cash flow conversion of 107% • Manufacturing results stabilising wit

  28. Slide 28: Strategic Focus for the Near Term – SA

    STRATEGIC FOCUS FOR THE NEAR TERM – SA • Outcomes from the strategic review of SA  Great potential in the Aspen portfolio and the market  Diverse portfolio which requires focus and continuous reassessment  The opportunity for growth in consumer health and OTC products was highlighted. Further liq

  29. Slide 29: Strategic Focus for the Near Term – SA Continued

    STRATEGIC FOCUS FOR THE NEAR TERM – SA CONTINUED PUBLIC SECTOR ARVs • Aspen has a social commitment to SA patients and continues to manufacture ARVs  Local manufacturing has seen no benefits in the supply of ARVs to SA tender  Aspen has continually stepped in for other providers • ARVs have foreig

  30. Slide 30: Strategic Focus for the Near Term – Europe

    STRATEGIC FOCUS FOR THE NEAR TERM – EUROPE • Outcomes from the strategic review  Where we have a larger sales representation - performance was enhanced  In some regions, in terms of commericalisation capabilities, we are sub-scale  Aspen is positioned to be a “partner of choice” within non-commod

  31. Slide 31: Opportunities

    OPPORTUNITIES • Heparin API  Committed building of safety stock of heparin API  18 months of API in stock at Oss with additional stock being held at the NdB facility  Market price of API has increased significantly  Gains to be made from recommencing sales to third party customers • HPC  FDA AN

  32. Slide 32: Efficient and Effective De-leveraging

    EFFICIENT AND EFFECTIVE DE-LEVERAGING 31 December 2018 R53.5 bn CY 2018* R11.7 bn R14.5 bn -27% -8% decline in decline in normalised net debt EBITDA 30 June 2019 FY 2019^ R39.0 bn R10.8 bn Net debt Normalised EBITDA *Including discontinued operations disposed of ^Excluding discontinued operations di

  33. Slide 33: Outlook

    OUTLOOK FY 2020 EXPECTED TO DELIVER A STRONGER H2 VS H1 • Europe CIS  Sterile Focus Brands, flat to positive growth expected FY 2020  H1 2020 expected to be down approximately -5%  Commercial intervention and Anaesthetics supply to drive a stronger H2 2020  Regional Brands down 5% - 10% • Aspen

  34. Slide 34: Appendix

    >< (a) za Lo Oo oO <x

  35. Slide 35: Appendix 1: Abridged Statement of Comprehensive Income

    APPENDIX 1: ABRIDGED STATEMENT OF COMPREHENSIVE INCOME CONTINUING AND DISCONTINUED R’million FY 2019 FY 2018* % change Net revenue 38 872 38 314 1% Cost of sales (19 174) (18 628) Gross profit 19 698 19 686 0% Gross profit margin 50.7% 51.4% Operating expenses (9 943) (9 576) Net other operating exp

  36. Slide 36: Appendix 2: Abridged Statement of Normalised Comprehensive Income

    APPENDIX 2: ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME CONTINUING R’million FY 2019 FY 2018 * % change FY 2018 (CER) % change Net revenue 38 872 38 314 1% 39 856 -2% Cost of sales (19 174) (18 628) 3% (19 661) Gross profit 19 698 19 686 0% 20 195 -2% Gross profit margin 50.7% 51.4% 50.7%

  37. Slide 37: Appendix 3: Reconciliation of Reported NHEPS

    APPENDIX 3: RECONCILIATION OF REPORTED NHEPS CONTINUING AND DISCONTINUED Cents FY 2019 FY 2018* % change Basic earnings per share (EPS) 1 573.6 1 322.5 19% Profit on sale of property, plant and equipment 3.7 - >100% Impairment of property, plant and equipment 92.5 11.0 >100% Impairment of intangible

  38. Slide 38: Appendix 4: Group Statement of Financial Position

    APPENDIX 4: GROUP STATEMENT OF FINANCIAL POSITION R'million FY 2019 FY 2018* R‘million FY 2019 FY 2018* TOTAL ASSETS EQUITY AND LIABILIITIES Non-current assets 86 876 92 614 Shareholders equity 54 925 49 375 Intangible assets 67 180 72 163 Non-current liabilities 48 064 54 532 Property, plant and eq

  39. Slide 39: Appendix 5: Extract from Group Statement of Cash Flows

    APPENDIX 5: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS CONTINUING AND DISCONTINUED R’million FY 2019 FY 2018 % change Cash operating profit 10 918 11 925 -8% Changes in working capital (1 378) (1 597) -14% Cash generated from operations 9 540 10 328 -8% Net finance costs paid (1 742) (1 816) -4% Tax

  40. Slide 40: Appendix 6: IFRS Restatements

    APPENDIX 6: IFRS RESTATEMENTS Statement of comprehensive income R'million Reported previously Discontinued operations Adoption of IFRS 15 FY 2018 The implementation of IFRS 15: Revenue Revenue 42 596 (4 239) (43) 38 314 from Contracts with Customers and IFRS 9: Cost of sales (20 991) 2 302 61 (18 62

  41. Slide 41: Appendix 7: Net Funding Costs

    APPENDIX 7: NET FUNDING COSTS CONTINUING R’million FY 2019 FY 2018 Net interest paid (1 619) (1 411) Foreign exchange (losses)/gains (66) 88 Notional interest on financial instruments (274) (408) Normalised net funding costs (1 959) (1 731) Debt raising fees on acquisitions (70) (209) Foreign exchan

  42. Slide 42: Appendix 8: Group Revenue by Region

    APPENDIX 8: GROUP REVENUE BY REGION CONTINUING R’million FY 2019 FY 2018 * % Change FY 2018 (CER)** % Change Developed Europe 12 095 12 316 -2% 13 022 -7% Sub-Saharan Africa 8 575 8 855 -3% 8 978 -4% Asia Pacific 10 872 9 894 10% 10 411 4% Latin America 3 083 2 930 5% 2 910 6% Developing Europe & CI

  43. Slide 43: Appendix 9: Commercial Pharma Revenue Segment

    APPENDIX 9: COMMERCIAL PHARMA REVENUE SEGMENT CONTINUING – PREVIOUS DISCLOSURE R’million FY 2019 FY 2018* % change FY 2018 (CER)** % change Regional Brands 17 817 17 321 3% 17 736 0% Regional Brands 13 565 13 043 4% 13 246 2% High Potency & Cytotoxics 4 252 4 278 -1% 4 490 -5% Sterile Focus Brands 1

  44. Slide 44: Appendix 10: Working Capital Reconciliations

    APPENDIX 10: WORKING CAPITAL RECONCILIATIONS CONTINUING R’million FY 2019 FY 2018 Net Working capital - Reported 17 288 18 154 Less IFRS 9 and 15 restatement - (729) Net working capital - Restated 17 288 17 425 Fx impact - (18) Net working capital (CER) 17 288 17 407 Nutritionals - held for sale - (

  45. Slide 45: Appendix 11: Disposal of the Nutritionals Business

    APPENDIX 11: DISPOSAL OF THE NUTRITIONALS BUSINESS DISCONTINUED Profit on disposal R'million Proceeds on disposal R'million Gross proceeds 12 079 Gross proceeds 12 079 Cash disposed (63) Cash disposed (63) Cash proceeds 12 016 Cash proceeds 12 016 NAV disposed (6 294) JV buy-outs (1 016) Provisions

  46. Slide 46: Appendix 12: Institutional Investors – By Region

    APPENDIX 12: INSTITUTIONAL INVESTORS – BY REGION Rest of world, 9.0% Switzerland, 1.4% Singapore, 1.9% UK, 4.5% USA, 14.2% South Africa, 69.1% 46

  47. Slide 47: Appendix 13: Portfolio Management Model

    APPENDIX 13: PORTFOLIO MANAGEMENT MODEL Maximise portfolio Build portfolio Reshape portfolio returns Drivers of portfolio Aspen Portfolio strategy Sales & Supply Acquire Develop Collaborate Manufacturing Revitalise Collaborate Divest Marketing Chain Patients Needs Proactively seek Leverage Strategic

Aspen Pharmacare Holdings — FY2019 Earnings Presentation on 6ix